Hansa Biopharma, which recently announced plans to restructure, has appointed Evan Ballantyne as Chief Financial Officer (CFO), effective March 1, 2024. He succeeds Donato Spota, who will leave the company on February 28.
 
As CFO, Ballantyne will be responsible for developing and implementing the company’s corporate financial strategy and activities including financial reporting and investor relations (IR). He will report to President & Chief Executive Officer Søren Tulstrup and serve as a member of Hansa’s Executive Committee.

Experience

Most recently, Ballantyne was Senior Vice President, Chief Financial Officer at Gain Therapeutics, Inc. (Gain), a US-based biotech company. He brings more than 30 years of international experience as a senior financial executive in both public and private life science companies.
 
Søren Tulstrup, President and CEO, Hansa Biopharma said, “I am thrilled to welcome Evan to Hansa Biopharma at this pivotal and exciting time. With his deep international experience and successful track record as a CFO at public and private companies I am confident Evan will be a strong addition to our team and help drive our financial strategy, deliver on key strategic priorities, and build shareholder value.  With Evan on the team, we will continue to position Hansa as a burgeoning global commercial-stage biotech company with an exciting pipeline and strong commercial potential.”
 
Evan Ballantyne commented, “I am very excited to join Hansa Biopharma – its validated scientific platform, strong development programs in areas of high unmet need, and ongoing successful commercialization of its lead medicine are strong reasons to believe the Company has the potential to create significant value for all key stakeholders by delivering new treatments for serious immunological diseases. I believe my deep expertise in helping biotech companies navigate complex financial and investment opportunities and challenges aligns well with where Hansa is in its journey and the exciting opportunities ahead. I look forward to working with Søren, the Board of Directors, and the entire leadership team to advance the Company’s strategic priorities.”